US9464111B2 - Short peptides and a method of use as an antioxidant - Google Patents
Short peptides and a method of use as an antioxidant Download PDFInfo
- Publication number
- US9464111B2 US9464111B2 US14/315,619 US201414315619A US9464111B2 US 9464111 B2 US9464111 B2 US 9464111B2 US 201414315619 A US201414315619 A US 201414315619A US 9464111 B2 US9464111 B2 US 9464111B2
- Authority
- US
- United States
- Prior art keywords
- polypeptide
- composition
- amino acid
- capacity
- short chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 109
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 98
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 title claims description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract description 85
- 150000001413 amino acids Chemical group 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 17
- 230000007935 neutral effect Effects 0.000 claims abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004475 Arginine Substances 0.000 claims abstract description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004472 Lysine Substances 0.000 claims abstract description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 12
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 59
- 235000001014 amino acid Nutrition 0.000 description 58
- 235000006708 antioxidants Nutrition 0.000 description 23
- -1 peroxyl radicals Chemical class 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108010087806 Carnosine Proteins 0.000 description 6
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940044199 carnosine Drugs 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 0 CSCCC(NC(=O)C(CC(=O)C(CCCn[c+](n)n)NC(=O)C([NH3+])CCCn[c+](n)n)CC1=CNC=N1)C(=O)[O-].[NH3+]C(CC1=CNC=N1)C(=O)NC(Cc1ccc(O)cc1)C(=O)CC(CC1=CNC=N1)C(=O)NC(Cc1ccc(O)cc1)C(=O)[O-].n[c+](n)nCCCC([NH3+])C(=O)NC(Cc1ccc(O)cc1)C(=O)CC(CC1=CNC=N1)C(=O)NC(Cc1cnc2ccccc12)C(=O)[O-] Chemical compound CSCCC(NC(=O)C(CC(=O)C(CCCn[c+](n)n)NC(=O)C([NH3+])CCCn[c+](n)n)CC1=CNC=N1)C(=O)[O-].[NH3+]C(CC1=CNC=N1)C(=O)NC(Cc1ccc(O)cc1)C(=O)CC(CC1=CNC=N1)C(=O)NC(Cc1ccc(O)cc1)C(=O)[O-].n[c+](n)nCCCC([NH3+])C(=O)NC(Cc1ccc(O)cc1)C(=O)CC(CC1=CNC=N1)C(=O)NC(Cc1cnc2ccccc12)C(=O)[O-] 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- AZXGXVQWEUFULR-UHFFFAOYSA-N 2',4',5',7'-tetrabromofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 AZXGXVQWEUFULR-UHFFFAOYSA-N 0.000 description 3
- SOFRHZUTPGJWAM-UHFFFAOYSA-N 3-hydroxy-4-[(2-methoxy-5-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound COc1ccc(cc1N=Nc1c(O)c(cc2ccccc12)C(=O)Nc1cccc(c1)[N+]([O-])=O)[N+]([O-])=O SOFRHZUTPGJWAM-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229940097156 peroxyl Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- ZZOKVYOCRSMTSS-UHFFFAOYSA-M 9h-fluoren-9-ylmethoxymethanimidate Chemical compound C1=CC=C2C(COC(=O)[NH-])C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-M 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 2
- 210000004896 polypeptide structure Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 101800000068 Antioxidant peptide Proteins 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- LMYXEOXVZPKPTC-UHFFFAOYSA-O CC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)C(Cc1ccc(O)cc1)NC(=O)C([NH3+])CC1=CNC=N1)CC1=CNC=N1 Chemical compound CC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)C(Cc1ccc(O)cc1)NC(=O)C([NH3+])CC1=CNC=N1)CC1=CNC=N1 LMYXEOXVZPKPTC-UHFFFAOYSA-O 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000686495 Platymeris rhadamanthus Venom redulysin 2 Proteins 0.000 description 1
- 101100396933 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) imm2 gene Proteins 0.000 description 1
- 101100396930 Pseudomonas aeruginosa imm1 gene Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- PZTQVMXMKVTIRC-UHFFFAOYSA-L chembl2028348 Chemical compound [Ca+2].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 PZTQVMXMKVTIRC-UHFFFAOYSA-L 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A23L1/3006—
-
- A23L1/305—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/30—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing heterocyclic ring with at least one nitrogen atom as ring member
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- Antioxidants are compounds which can delay or inhibit the oxidation of organic molecules by inhibition of the initiation and/or propagation of oxidizing chain reactions, generally free radical reactions.
- Species associated with free radical oxidation processes include peroxyl radicals (ROO.), superoxide radicals (O 2 . ⁇ ) and hydroxyl radicals (.OH).
- ROO. peroxyl radicals
- O 2 . ⁇ superoxide radicals
- .OH hydroxyl radicals
- Many natural and synthetic molecules have antioxidant properties and such character has been quantified, collected and published by the United States Department of Agriculture by listing of oxygen radical absorbance capacities (ORAC). Generally, a wide range of spices, fruits, berries and legumes have been identified as having antioxidant properties. Natural antioxidants provide platforms for the quenching of free radicals.
- antioxidants include Vitamin C, Carnosine and Resveratrol.
- Carnosine ⁇ -alanyl-histidine
- a pH buffer ion-chelating agent
- lipid peroxidation in vitro.
- Proteins have also been shown to have antioxidative activities against free radical oxidation of lipids and/or fatty acids. Certain peptides having electron donor properties can react with free radicals to terminate the radical chain reaction, although the exact mechanism of action for such antioxidant peptides is not clearly known. Some aromatic amino acids and histidine have been reported to play a vital role in peptides having antioxidant properties.
- the present inventors have studied the antioxidant properties of short polypeptide molecules and have surprisingly learned specific structure activity relationships which have led to the discovery of short chain polypeptides having antioxidant activity comparable to or better than conventionally known antioxidants such as Vitamin C, Resveratrol and Carnosine which are also cost effective.
- an object of the present invention is to provide novel short chain polypeptides that have high antioxidant activity and are structurally tailored for a specific utility.
- the short chain polypeptides must be biologically safe and ideally at least economically competitive with the conventionally employed antioxidants described above.
- a further object of the present invention is to provide a method to protect a composition from oxidation or to impart antioxidant properties to a composition.
- An even further objective of the present invention is to provide a method to protect a keratinous material from free radical degradation.
- the short chain polypeptide comprises four amino acids.
- the present invention includes a method to protect a composition from oxidation wherein the short chain polypeptide of the first embodiment is added to the composition.
- the present invention includes a method to protect a keratinous material from free radical degradation by application of a composition containing the short chain polypeptide of the first embodiment to the keratinous material.
- the words “a” and “an” and the like carry the meaning of “one or more.”
- the phrases “selected from the group consisting of,” “chosen from,” and the like include mixtures of the specified materials.
- Terms such as “contain(s)” and the like are open terms meaning ‘including at least’ unless otherwise specifically noted. Where a numerical limit or range is stated, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.
- amino acid sequence description is provided by the one letter abbreviation sequence stated with the N-terminal end (N-terminus) amino acid first in the sequence and ending with the carboxyl terminal (carboxy terminus) amino acid.
- sequence RYHM SEQ ID NO:4 is a polypeptide containing four amino acids linked via peptide bonds in the order from N-terminus to carboxy terminus: arginine-tyrosine-histidine-methionine.
- carboxyl terminus of the sequence is designated with —NH 2
- the end carboxyl group is in the form of an amide.
- the N terminal group is derivatized, the nature of the derivative is designated by standard organic chemistry abbreviations. For example, “Ac” indicates an acetyl group.
- a short chain polypeptide contains 2 to 10 amino acids linked through a sequence of peptide bonds.
- amino acids may be grouped according to the chemical structure of the side chain.
- glycine, alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine and proline are described as nonpolar (hydrophobic) amino acids.
- Serine, threonine, cysteine, tyrosine, asparagine and glutamine are described as polar (hydrophilic), neutrally charged amino acids.
- Aspartic acid (aspartate) and glutamic acid (glutamate) are ionic with a negative charge and lysine, arginine and histidine are ionic with a positive charge (basic).
- polypeptides are an interesting class of molecules that have the potential to meet all the criteria for development of novel new antioxidants.
- the present invention is a short chain polypeptide, comprising: 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
- Tables I to IX shown below are a compilation of polypeptides studied by the inventors to ascertain those elements of the molecular structure that contribute to or negate antioxidant activity.
- polypeptides were prepared by conventional synthesis methods and screened in tubo for antioxidant activity for peroxyl radicals (ROO.), superoxide radicals (O 2 . ⁇ ) and hydroxyl radicals (.OH).
- short chain polypeptides having neutral and/or hydrophobic amino acids at the N-terminal exhibited low or limited activity in HORAC and SORAC.
- Table IV shows that polypeptides having a negatively charged amino acid at the N-terminus have no activity according to both ORAC and HORAC, while Table V shows that short chain polypeptides having a positive charged (basic) amino acid at the N-terminus have high HORAC activity.
- the HORAC activity is 10,000 ⁇ mol GAE/g or higher and is significantly greater than the values shown in any of the previous Tables.
- Table VI shows that short chain polypeptides of four or less amino acids having a net sum of positive charge across the side chain structures have the greatest overall antioxidant activity.
- Table VII a polypeptide structure having high net positive charge, but not containing a neutral or hydrophobic amino acid had no ORAC activity.
- Table VIII inclusion of at least one hydrophobic and/or neutral amino acid in the amino acid sequence after the N-terminal amino acid leads to significantly higher antioxidant activity as demonstrated by the ORAC values.
- the first amino acid should be positively charged as a neutrally/hydrophobic and/negatively charged amino acid has limited to low antioxidant activity, especially for HORAC.
- an overall positive charge is a crucial factor contributing to antioxidant activity
- a hydrophobic/neutrally charged amino acid within the chain subsequent to the N-terminal amino acid is necessary for increased activity as seen in ORAC activity.
- the presence of negatively charged amino acids eliminates any antioxidant activity of the short chain polypeptide.
- the short chain polypeptide of the present invention contains four amino acids.
- the inventors have taken all the information obtained from the study described above as indicated from Tables III to IX and designed the short chain polypeptides of formulas (I) to (IV) (SEQ ID NOS:1-4) as explicit embodiments of the present invention.
- the structural formulas, mass weights, single letter abbreviation and net polypeptide charge for each of the novel short chain polypeptides are shown in Table I.
- ORAC, HORAC and SOD test results for each of the structures of formulas (I) to (IV) are shown in Table II.
- antioxidant results for Vitamin C, Carnosine and Resveratrol are shown in Table II.
- the short chain polypeptides according to the present invention have ORAC activity comparable to those of the conventional antioxidants, while having significantly higher HORAC activity. Such increased HORAC activity is an unexpected and significant improvement obtained with the compounds of the present invention.
- the present invention also includes a method to prepare a composition having antioxidant properties.
- the method includes adding a short chain polypeptide according to the first embodiment to the composition.
- the short chain polypeptide added comprises 2 to 4 amino acids bonded to form the polypeptide chain, wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid of the polypeptide chain is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
- the short chain polypeptide may be one or more of compounds of formulas (I) to (IV).
- the composition may be of any physical form including, for example, a solid, a paste, a cream, a gel or a liquid.
- the composition may be a solution, a dispersion, an emulsion or a suspension.
- the content of the short chain polypeptide according to the invention will depend upon the nature and intended use of the composition and may be easily formulated by one of ordinary skill in the respective technology of the composition.
- the content of the short chain antioxidant polypeptide of the invention may be from 0.01 to 40 wt % of the total weight of the composition.
- the content is not limited and depending on a given utility, a content different from the range of 0.01 to 40 wt % may be employed.
- the present invention includes a composition comprising a short chain polypeptide, according to the first embodiment to the composition.
- the short chain polypeptide added comprises 2 to 4 amino acids bonded to form the polypeptide chain, wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid of the polypeptide chain is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
- a short chain polypeptide of the invention may be advantageously formulated in a composition that may be in any galenical form normally available for the intended indication and mode of administration.
- the composition may comprise a physiologically or pharmaceutically acceptable medium.
- a topical composition according to the invention may advantageously be formulated in any galenical form that is suitable for caring for the skin and its integuments, and may be in the form of ointments, creams, solutions, gels, emulsions, foams or aerosol compositions containing a propellant, milks, pomades, powders, impregnated pads, lotions or suspensions.
- a composition intended for topical administration may be an aqueous, aqueous-alcoholic or oily solution, a solution or a dispersion of the lotion or serum type, an emulsion of liquid or semiliquid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O/W) or conversely (W/O), a suspension or an emulsion, of soft, semisolid or solid consistency, of the cream type or of the aqueous or anhydrous gel type, a multiple emulsion (W/O/W or O/W/O), a microemulsion, a nanoemulsion, a preparation of microcapsules, a preparation of microparticles, a vesicular dispersion of ionic and/or nonionic type, or a wax/aqueous phase dispersion.
- compositions in accordance with the invention for oral administration the use of an ingestible support, whose nature is adapted according to the type of composition under consideration, is preferred.
- oral composition means, for example, nutritional, nutraceutical, cosmeceutical or pharmaceutical compositions comprising at least one compound according to the invention.
- the formulation of the oral compositions according to the invention may be performed via any common process known to those skilled in the art for producing drinkable solutions, coated tablets, gel capsules, gels, emulsions, tablets to be swallowed or chewed, capsules, especially soft or hard capsules, granules to be dissolved, syrups, solid or liquid foods and hydrogels allowing controlled release, food bars, powders, in compacted or non-compacted form, liquid solutions or suspensions, confectioneries, fermented milk, fermented cheeses, chewing gums, toothpastes or spray solutions.
- a short chain polypeptide of the invention may moreover be formulated with the usual excipients and components for such oral compositions or food supplements, i.e. especially fatty and/or aqueous components, humectants, thickeners, preserving agents, texture agents, taste agents and/or coating agents, and/or antioxidants.
- excipients and components for such oral compositions or food supplements i.e. especially fatty and/or aqueous components, humectants, thickeners, preserving agents, texture agents, taste agents and/or coating agents, and/or antioxidants.
- a composition according to the invention may also comprise any formulating agent or any cosmetically or dermatologically acceptable additional active agent.
- the amounts of these various active agents are those conventionally used in the field under consideration, and are especially determined so as not to affect the desired properties for a compound of the invention or for a composition of the invention.
- the short chain polypeptides according to the present invention may be included in nutritional compositions as an antioxidant or stabilizer of the composition that may also function as a solubilizer or as a dispersant.
- the short chain polypeptides according to the invention may be combined with other antioxidants to stabilize a composition to a broad spectrum of oxidative degradation mechanisms.
- the composition may contain nutrient fats, oils and/or proteins and may be aqueous or oil based solutions or emulsions or dry powders.
- other antioxidants known to one of skill in the art may be employed in combination with the short chain polypeptides of the present invention.
- adjuvant antioxidants may include, but are not limited to butylated hydroxy toluene, ⁇ - or ⁇ -carotene, citric acid or a derivative thereof, p-aminobenzoic acid, tocopherols and vitamins e, k and q10.
- adjuvant antioxidants may include, but are not limited to butylated hydroxy toluene, ⁇ - or ⁇ -carotene, citric acid or a derivative thereof, p-aminobenzoic acid, tocopherols and vitamins e, k and q10.
- One of ordinary skill may formulate an effective anti-oxidant combination for a nutritional composition employing conventional laboratory test methods.
- the present invention provides a method for attenuating effects of free radicals on a keratinous material by application of the composition described above to the keratinous material.
- the keratinous material may be human skin or hair and the composition may be in the form of, for example, a sunscreen, a skin cream, a shampoo or a hair conditioner.
- the composition may be of any physical form including, for example, a solid, a paste, a cream, a gel or a liquid.
- the composition may be a solution, a dispersion, an emulsion or a suspension.
- the content of the short chain polypeptide according to the invention will depend upon the nature and intended use of the composition and may be easily formulated by one of ordinary skill in the respective technology of the composition.
- the content of the short chain antioxidant polypeptide of the invention may be from 0.01 to 40 wt % of the total weight of the composition.
- the content is not limited and depending on a given utility, a content different from the range of 0.01 to 40 wt % may be employed.
- the short chain polypeptide may be one or more of compounds of formulas (I) to (IV).
- the present invention provides a method to protect a keratinous material from free radical degradation by application of the composition described above to the keratinous material.
- the keratinous material may be human skin or hair and the composition may be in the form of, for example, a sunscreen, a skin cream, a shampoo or a hair conditioner.
- N- ⁇ -Fmoc-L-amino acids, Fmoc-amide resin and reagents used for peptide synthesis were obtained from Iris Biotech. Solvents were analytical grade products from ThermoFisher. The three peptides were chemically synthesized by the solid phase method using an automated peptide synthesizer (Applied A433). Peptide chains were assembled stepwise on 0.75 meq of Fmoc-amide resin using 1 mmol of Fmoc L-amino acids.
- Fmoc-amino acids (lmmol)
- activator 0.5 M HOBT/HBTU in dimethylformamide
- base 2 M diisopropylethylamine in N-methyl-pyrrolidone
- deprotecting mixture (20% piperidine in N-methyl-pyrrolidone).
- peptidyl-resins were treated 2 h at room temperature with a mixture of TFA/water/phenol/thioanisole/ethanedithiol (92.5/2/1/2.5/2). The peptide mixtures were then filtered, and the filtrates were precipitated by adding cold diethylether. The crude peptides were pelleted by centrifugation (3,000 g; 10 min), and the supernatants were discarded.
- Peptides were purified by C18 reversed-phase (RP) High Performance/Pressure Liquid Chromatography (HPLC) using an Onyx Jupiter column (250 ⁇ 10 mm, 50. Elution of the peptides was performed with a linear gradient of 0 to 40% acetonitrile in 0.1% TFA (run duration of 150 min). The collected fractions were analyzed for their peptide content by analytical C18 RP-HPLC (Onyx monolithic column, 100 ⁇ 4.6 mm). The target peptides were characterized by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry.
- MALDI-TOF matrix-assisted laser desorption ionization-time-of-flight
- Peptides according to the present invention are listed in Table I.
- the Table shows the sequence of the peptide in one-letter abbreviation, the structural formula, the molecular weight and the net charge of the tetrapeptide.
- the peptides were tested in tubo for their antioxidant properties and tested against reference/known antioxidants.
- the evaluation of the antioxidant properties were conducted by determination of the ORAC (USTM 192), HORAC (USTM 190) and SOD (USTM 193) test methods.
- the results are listed in Table II for the peptides of the invention and for the conventionally known antioxidants
- Table IV shows the results obtained for short chain polypeptides having a negatively charged amino acid at the N-terminal. These sequences have no activity in both ORAC and HORAC.
- Table V shows the results obtained for short chain polypeptides having a positively charged amino acid at the N-terminal.
- Table VI shows the results obtained for polypeptides having four or less amino acids.
- Table VII shows the results obtained for a short chain polypeptide having a positive charge (2.5+) is important to contributing to HORAC activity, the lack of a hydrophobic/neutrally charged amino acid has given this sequence no capacity in ORAC activity.
- Table VIII below indicates that the presence of at least one neutral and/or hydrophobic amino acid in the chain after the N-terminal amino acid contributes to the ORAC activity.
- Table IX shows results obtained for polypeptides containing a negatively charged amino acid. These sequences have no activity in both ORAC and HORAC. It shows that despite the presence of positively charge amino acids and neutral/hydrophobic amino acids, these peptide sequences have no antioxidant activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group. A method to prepare a composition having antioxidant activity and a composition having antioxidant activity are also provided.
Description
Antioxidants are compounds which can delay or inhibit the oxidation of organic molecules by inhibition of the initiation and/or propagation of oxidizing chain reactions, generally free radical reactions. Species associated with free radical oxidation processes include peroxyl radicals (ROO.), superoxide radicals (O2.−) and hydroxyl radicals (.OH). Many natural and synthetic molecules have antioxidant properties and such character has been quantified, collected and published by the United States Department of Agriculture by listing of oxygen radical absorbance capacities (ORAC). Generally, a wide range of spices, fruits, berries and legumes have been identified as having antioxidant properties. Natural antioxidants provide platforms for the quenching of free radicals.
Conventionally employed biologically safe antioxidants include Vitamin C, Carnosine and Resveratrol. Carnosine (β-alanyl-histidine) is a natural dipeptide that is innate to vertebrates and found to act as a pH buffer, ion-chelating agent and in lipid peroxidation in vitro. Such activity for Carnosine spurs interest in peptide structures, because peptides offer a wide variety of structural modification and molecular design possibilities upon which antioxidant molecules of designed properties may be prepared.
Proteins have also been shown to have antioxidative activities against free radical oxidation of lipids and/or fatty acids. Certain peptides having electron donor properties can react with free radicals to terminate the radical chain reaction, although the exact mechanism of action for such antioxidant peptides is not clearly known. Some aromatic amino acids and histidine have been reported to play a vital role in peptides having antioxidant properties.
In view of growing demand for antioxidants designed for attractive cost and structure activity performance that may be used in food, cosmetic and other applications, economical antioxidants based on natural product raw material building blocks are sought. Proteins or long chain polypeptides having interesting antioxidant properties are known; however, the cost of producing synthetic peptides are five to twenty times higher than the cost of conventional antioxidants.
Therefore, the present inventors have studied the antioxidant properties of short polypeptide molecules and have surprisingly learned specific structure activity relationships which have led to the discovery of short chain polypeptides having antioxidant activity comparable to or better than conventionally known antioxidants such as Vitamin C, Resveratrol and Carnosine which are also cost effective.
Therefore an object of the present invention is to provide novel short chain polypeptides that have high antioxidant activity and are structurally tailored for a specific utility. The short chain polypeptides must be biologically safe and ideally at least economically competitive with the conventionally employed antioxidants described above.
A further object of the present invention is to provide a method to protect a composition from oxidation or to impart antioxidant properties to a composition.
An even further objective of the present invention is to provide a method to protect a keratinous material from free radical degradation.
These and other objects have been achieved by the present invention, the first embodiment of which includes a short chain polypeptide, comprising: 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
In one embodiment of the present invention, the short chain polypeptide comprises four amino acids.
In another embodiment, the present invention includes a method to protect a composition from oxidation wherein the short chain polypeptide of the first embodiment is added to the composition.
In a further embodiment, the present invention includes a method to protect a keratinous material from free radical degradation by application of a composition containing the short chain polypeptide of the first embodiment to the keratinous material.
The foregoing paragraphs have been provided by way of general introduction, and are not intended to limit the scope of the following claims. The described embodiments, together with further advantages, will be best understood by reference to the following detailed description taken in conjunction with the appended claims.
As used herein, the words “a” and “an” and the like carry the meaning of “one or more.” The phrases “selected from the group consisting of,” “chosen from,” and the like include mixtures of the specified materials. Terms such as “contain(s)” and the like are open terms meaning ‘including at least’ unless otherwise specifically noted. Where a numerical limit or range is stated, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.
Additional advantages and other features of the present invention will be set forth in part in the description that follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from the practice of the present invention. The advantages of the present invention may be realized and obtained as particularly pointed out in the appended claims. As will be realized, the present invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the present invention. In this regard, the description herein is to be understood as illustrative in nature, and not as restrictive.
In the following description peptide sequences are described in terms of one-letter abbreviations of the amino acids according to the following chart.
Abbre- | Abbre- | Abbre- | |||
Amino acid | viation | Amino Acid | viation | Amino Acid | viation |
Alanine | A | Arginine | R | Asparagine | N |
Aspartate | D | Cysteine | C | Glutamate | E |
Glutamine | Q | Glycine | G | Histidine | H |
Isoleucine | I | Leucine | L | Lysine | K |
Methionine | M | Phenylalanine | F | Proline | P |
Serine | S | Threonine | T | Tryptophan | W |
Tyrosine | Y | Valine | V | ||
The capital case letters represent naturally occurring amino acids in the L configuration. When a lower case letter is shown, the amino acid is in the D configuration.
According to conventional practice amino acid sequence description is provided by the one letter abbreviation sequence stated with the N-terminal end (N-terminus) amino acid first in the sequence and ending with the carboxyl terminal (carboxy terminus) amino acid. For example, the sequence RYHM (SEQ ID NO:4) is a polypeptide containing four amino acids linked via peptide bonds in the order from N-terminus to carboxy terminus: arginine-tyrosine-histidine-methionine. When the carboxyl terminus of the sequence is designated with —NH2, the end carboxyl group is in the form of an amide. When the N terminal group is derivatized, the nature of the derivative is designated by standard organic chemistry abbreviations. For example, “Ac” indicates an acetyl group.
Throughout the following description, terms such as “polypeptide,” “short chain polypeptide” and peptide molecule may be used interchangeably. According to the present invention, a short chain polypeptide contains 2 to 10 amino acids linked through a sequence of peptide bonds.
As understood by one of ordinary skill, the amino acids may be grouped according to the chemical structure of the side chain. Thus glycine, alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine and proline are described as nonpolar (hydrophobic) amino acids. Serine, threonine, cysteine, tyrosine, asparagine and glutamine are described as polar (hydrophilic), neutrally charged amino acids. Aspartic acid (aspartate) and glutamic acid (glutamate) are ionic with a negative charge and lysine, arginine and histidine are ionic with a positive charge (basic).
Standard abbreviations conventionally employed in organic chemistry may also be employed. As an example, “Ac” represents an acetyl group.
In the study of and search for molecules that have potent antioxidant activity and at the same time are biologically safe, economical to produce and may be tailored for physical properties including bioavailability, solubility and dispersibility, the inventors have recognized that polypeptides are an interesting class of molecules that have the potential to meet all the criteria for development of novel new antioxidants.
Thus a study was undertaken to understand the structural property and molecular composition parameters of polypeptide molecules that contribute to maximum antioxidant activity.
As a result of this study, the inventors have discovered the present invention, the first embodiment of which is a short chain polypeptide, comprising: 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
Tables I to IX shown below are a compilation of polypeptides studied by the inventors to ascertain those elements of the molecular structure that contribute to or negate antioxidant activity. In the course of the study, polypeptides were prepared by conventional synthesis methods and screened in tubo for antioxidant activity for peroxyl radicals (ROO.), superoxide radicals (O2.−) and hydroxyl radicals (.OH).
In the screening standard testing for oxygen radical absorbance capacity (ORAC), hydroxyl radical absorbance capacity (HORAC), superoxide radical absorbance capacity (SORAC) and superoxide dismutase activity (SOD) were conducted with the test polypeptides. Testing was conducted according to USTM 190 (HORAC), USTM 191 (SORAC), USTM 192 (ORAC) and USTM 193 (SOAC) (SOD). Upon review of the results as indicated in the Tables, the inventors have discovered certain elements of the polypeptide structure as recited in claim 1 that are key contributors to determination of antioxidant activity.
Thus as shown in Table III, short chain polypeptides having neutral and/or hydrophobic amino acids at the N-terminal exhibited low or limited activity in HORAC and SORAC. Table IV shows that polypeptides having a negatively charged amino acid at the N-terminus have no activity according to both ORAC and HORAC, while Table V shows that short chain polypeptides having a positive charged (basic) amino acid at the N-terminus have high HORAC activity. In fact, the HORAC activity is 10,000 μmol GAE/g or higher and is significantly greater than the values shown in any of the previous Tables.
Table VI shows that short chain polypeptides of four or less amino acids having a net sum of positive charge across the side chain structures have the greatest overall antioxidant activity. However as indicated by Table VII, a polypeptide structure having high net positive charge, but not containing a neutral or hydrophobic amino acid had no ORAC activity. Thus as shown in Table VIII, inclusion of at least one hydrophobic and/or neutral amino acid in the amino acid sequence after the N-terminal amino acid leads to significantly higher antioxidant activity as demonstrated by the ORAC values.
Further, the inventors have discovered, that even though a given sequence may contain positively charged amino acids and neutral and/or hydrophobic amino acids, inclusion of a negatively charged (acidic) amino acid in the chain leads to a molecule having no ORAC or HORAC activity.
Thus, the inventors have discovered that the placement of the sequence and overall positive charge are crucial factors that determine the antioxidant activity of the short chain polypeptide. The first amino acid should be positively charged as a neutrally/hydrophobic and/negatively charged amino acid has limited to low antioxidant activity, especially for HORAC. Though an overall positive charge is a crucial factor contributing to antioxidant activity, a hydrophobic/neutrally charged amino acid within the chain subsequent to the N-terminal amino acid is necessary for increased activity as seen in ORAC activity. Further, the presence of negatively charged amino acids eliminates any antioxidant activity of the short chain polypeptide.
In one preferred aspect of the first embodiment, the short chain polypeptide of the present invention contains four amino acids. The inventors have taken all the information obtained from the study described above as indicated from Tables III to IX and designed the short chain polypeptides of formulas (I) to (IV) (SEQ ID NOS:1-4) as explicit embodiments of the present invention.
The structural formulas, mass weights, single letter abbreviation and net polypeptide charge for each of the novel short chain polypeptides are shown in Table I. ORAC, HORAC and SOD test results for each of the structures of formulas (I) to (IV) are shown in Table II. Also shown in Table II are antioxidant results for Vitamin C, Carnosine and Resveratrol. As indicated in Table II, the short chain polypeptides according to the present invention have ORAC activity comparable to those of the conventional antioxidants, while having significantly higher HORAC activity. Such increased HORAC activity is an unexpected and significant improvement obtained with the compounds of the present invention.
In another embodiment, the present invention also includes a method to prepare a composition having antioxidant properties. The method includes adding a short chain polypeptide according to the first embodiment to the composition. Thus the short chain polypeptide added comprises 2 to 4 amino acids bonded to form the polypeptide chain, wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid of the polypeptide chain is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
In explicit aspects of this embodiment, the short chain polypeptide may be one or more of compounds of formulas (I) to (IV).
The composition may be of any physical form including, for example, a solid, a paste, a cream, a gel or a liquid. The composition may be a solution, a dispersion, an emulsion or a suspension. The content of the short chain polypeptide according to the invention will depend upon the nature and intended use of the composition and may be easily formulated by one of ordinary skill in the respective technology of the composition.
In general the content of the short chain antioxidant polypeptide of the invention may be from 0.01 to 40 wt % of the total weight of the composition. However, the content is not limited and depending on a given utility, a content different from the range of 0.01 to 40 wt % may be employed.
In a further embodiment, the present invention includes a composition comprising a short chain polypeptide, according to the first embodiment to the composition. Thus the short chain polypeptide added comprises 2 to 4 amino acids bonded to form the polypeptide chain, wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid of the polypeptide chain is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
A short chain polypeptide of the invention may be advantageously formulated in a composition that may be in any galenical form normally available for the intended indication and mode of administration. The composition may comprise a physiologically or pharmaceutically acceptable medium.
According to one embodiment, a topical composition according to the invention may advantageously be formulated in any galenical form that is suitable for caring for the skin and its integuments, and may be in the form of ointments, creams, solutions, gels, emulsions, foams or aerosol compositions containing a propellant, milks, pomades, powders, impregnated pads, lotions or suspensions. A composition intended for topical administration may be an aqueous, aqueous-alcoholic or oily solution, a solution or a dispersion of the lotion or serum type, an emulsion of liquid or semiliquid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O/W) or conversely (W/O), a suspension or an emulsion, of soft, semisolid or solid consistency, of the cream type or of the aqueous or anhydrous gel type, a multiple emulsion (W/O/W or O/W/O), a microemulsion, a nanoemulsion, a preparation of microcapsules, a preparation of microparticles, a vesicular dispersion of ionic and/or nonionic type, or a wax/aqueous phase dispersion.
In the case of a composition in accordance with the invention for oral administration, the use of an ingestible support, whose nature is adapted according to the type of composition under consideration, is preferred. Tablets, gel capsules or lozenges, suspensions, oral supplements in dry form and oral supplements in liquid form, milk, yoghurt, cheese, fermented milks, milk-based fermented products, ice creams, cereal-based products or fermented cereal-based products, milk-based powders, infant and baby formulae, food products of confectionery, chocolate or cereal type, and animal feed in particular for pets, are thus especially suitable as food supports.
The term “oral composition” means, for example, nutritional, nutraceutical, cosmeceutical or pharmaceutical compositions comprising at least one compound according to the invention. The formulation of the oral compositions according to the invention may be performed via any common process known to those skilled in the art for producing drinkable solutions, coated tablets, gel capsules, gels, emulsions, tablets to be swallowed or chewed, capsules, especially soft or hard capsules, granules to be dissolved, syrups, solid or liquid foods and hydrogels allowing controlled release, food bars, powders, in compacted or non-compacted form, liquid solutions or suspensions, confectioneries, fermented milk, fermented cheeses, chewing gums, toothpastes or spray solutions.
A short chain polypeptide of the invention may moreover be formulated with the usual excipients and components for such oral compositions or food supplements, i.e. especially fatty and/or aqueous components, humectants, thickeners, preserving agents, texture agents, taste agents and/or coating agents, and/or antioxidants. The formulating agents and excipients for oral compositions, and especially for food supplements, are known in this field and will not be the subject of a detailed description herein.
A composition according to the invention may also comprise any formulating agent or any cosmetically or dermatologically acceptable additional active agent. The amounts of these various active agents are those conventionally used in the field under consideration, and are especially determined so as not to affect the desired properties for a compound of the invention or for a composition of the invention.
In another embodiment, the short chain polypeptides according to the present invention may be included in nutritional compositions as an antioxidant or stabilizer of the composition that may also function as a solubilizer or as a dispersant. In other aspects of this embodiment, the short chain polypeptides according to the invention may be combined with other antioxidants to stabilize a composition to a broad spectrum of oxidative degradation mechanisms. The composition may contain nutrient fats, oils and/or proteins and may be aqueous or oil based solutions or emulsions or dry powders. In addition to the conventional antioxidants described above, other antioxidants known to one of skill in the art may be employed in combination with the short chain polypeptides of the present invention. Examples of adjuvant antioxidants may include, but are not limited to butylated hydroxy toluene, α- or β-carotene, citric acid or a derivative thereof, p-aminobenzoic acid, tocopherols and vitamins e, k and q10. One of ordinary skill may formulate an effective anti-oxidant combination for a nutritional composition employing conventional laboratory test methods.
In another embodiment, the present invention provides a method for attenuating effects of free radicals on a keratinous material by application of the composition described above to the keratinous material. The keratinous material may be human skin or hair and the composition may be in the form of, for example, a sunscreen, a skin cream, a shampoo or a hair conditioner.
The composition may be of any physical form including, for example, a solid, a paste, a cream, a gel or a liquid. The composition may be a solution, a dispersion, an emulsion or a suspension. The content of the short chain polypeptide according to the invention will depend upon the nature and intended use of the composition and may be easily formulated by one of ordinary skill in the respective technology of the composition.
In general the content of the short chain antioxidant polypeptide of the invention may be from 0.01 to 40 wt % of the total weight of the composition. However, the content is not limited and depending on a given utility, a content different from the range of 0.01 to 40 wt % may be employed.
In explicit aspects of this embodiment, the short chain polypeptide may be one or more of compounds of formulas (I) to (IV).
In another embodiment, the present invention provides a method to protect a keratinous material from free radical degradation by application of the composition described above to the keratinous material. The keratinous material may be human skin or hair and the composition may be in the form of, for example, a sunscreen, a skin cream, a shampoo or a hair conditioner.
The above description is presented to enable a person skilled in the art to make and use the invention, and is provided in the context of a particular application and its requirements. Various modifications to the preferred embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments and applications without departing from the spirit and scope of the invention. Thus, this invention is not intended to be limited to the embodiments shown, but is to be accorded the widest scope consistent with the principles and features disclosed herein. In this regard, certain embodiments within the invention may not show every benefit of the invention, considered broadly.
N-α-Fmoc-L-amino acids, Fmoc-amide resin and reagents used for peptide synthesis were obtained from Iris Biotech. Solvents were analytical grade products from ThermoFisher. The three peptides were chemically synthesized by the solid phase method using an automated peptide synthesizer (Applied A433). Peptide chains were assembled stepwise on 0.75 meq of Fmoc-amide resin using 1 mmol of Fmoc L-amino acids.
The following reagents were used: Fmoc-amino acids (lmmol), activator (0.5 M HOBT/HBTU in dimethylformamide), base (2 M diisopropylethylamine in N-methyl-pyrrolidone) and deprotecting mixture (20% piperidine in N-methyl-pyrrolidone).
After peptide chain assembly, peptidyl-resins were treated 2 h at room temperature with a mixture of TFA/water/phenol/thioanisole/ethanedithiol (92.5/2/1/2.5/2). The peptide mixtures were then filtered, and the filtrates were precipitated by adding cold diethylether. The crude peptides were pelleted by centrifugation (3,000 g; 10 min), and the supernatants were discarded.
Peptides were purified by C18 reversed-phase (RP) High Performance/Pressure Liquid Chromatography (HPLC) using an Onyx Jupiter column (250×10 mm, 50. Elution of the peptides was performed with a linear gradient of 0 to 40% acetonitrile in 0.1% TFA (run duration of 150 min). The collected fractions were analyzed for their peptide content by analytical C18 RP-HPLC (Onyx monolithic column, 100×4.6 mm). The target peptides were characterized by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry.
The purity of each peptide sample tested was >98%.
Peptides according to the present invention are listed in Table I. The Table shows the sequence of the peptide in one-letter abbreviation, the structural formula, the molecular weight and the net charge of the tetrapeptide.
TABLE I | ||||
Name | Sequence | Structure | Mass (g/mol) | Net Charge |
CP2 | RRHM | formula (I) | 598.31 | +2.5 |
(SEQ ID NO: 1) | ||||
AO1 | HYHY | formula (II) | 618.25 | +1 |
(SEQ ID NO: 2) | ||||
AO2 | RYHW | formula (III) | 680.31 | +1.5 |
(SEQ ID NO: 3) | ||||
AO2.1 | RYHM | formula (IV) | 605.27 | +1.5 |
(SEQ ID NO: 4) | ||||
The peptides were tested in tubo for their antioxidant properties and tested against reference/known antioxidants. The evaluation of the antioxidant properties were conducted by determination of the ORAC (USTM 192), HORAC (USTM 190) and SOD (USTM 193) test methods. The results are listed in Table II for the peptides of the invention and for the conventionally known antioxidants
TABLE II | ||||
ORAC/ | HORAC/ | SOD/ | ||
peroxyl, | hydroxyl, | superoxide, | ||
Sequence | μmol GAE/g | μmol GAE/g | Active50 (U/mg) | |
Name | ||||
CP2 | RRHM | 1204 | 321448 | |
(SEQ ID NO: 1) | ||||
AO1 | HYHY | 4748 | 33489 | 6 (Active25) |
(SEQ ID NO: 2) | ||||
AO2 | RYHW | 9328 | 41882 | 4 (Active25) |
(SEQ ID NO: 3) | ||||
AO2.1 | RYHM | 5390 | 132591 | |
(SEQ ID NO: 4) | ||||
Supplier | ||||
DSM | 4456 | 0 | 752 | |
Symrise | 354 | 2099 | 0 | |
Symrise | 25462 | 14190 | 626 (Active25) | |
Table III shows the results obtained for short chain polypeptides having a neutral and/or hydrophobic amino acid at the N-terminal.
TABLE III | ||||
Name | Sequence | ORAC | HORAC | SORAC |
RED9 | fkwR-NH2 | 2202 | 752 | No capacity |
RED25 | WKYK-NH2 | 4168 | 2476 | No capacity |
(SEQ ID NO: 5) | ||||
RED31 | wRwR-NH2 | 4652 | — | No capacity |
RED6 | WRYR-NH2 | 4488 | 1548 | No capacity |
(SEQ ID NO: 6) | ||||
RED18 | WrYr-NH2 | 4758 | 2982 | No capacity |
RED19 | WRYr-NH2 | 4350 | 1457 | No capacity |
RED20 | WrYR-NH2 | 4448 | 1666 | No capacity |
RED21 | WRyR-NH2 | 4816 | 2472 | 7(IC25) |
RED22 | wRyR-NH2 | 5383 | 1686 | No capacity |
RED24 | WRYR-NH2 | 4077 | 2225 | No capacity |
RED23 | WRYR | 4091 | 2089 | No capacity |
(SEQ ID NO: 6) | ||||
RED29 | wRyRw-NH2 | 5512 | — | No capacity |
RED28 | wRyRy-NH2 | 5216 | — | 3(IC25) |
RED34 | YkYkYk | 355 | 1053 | — |
Table IV shows the results obtained for short chain polypeptides having a negatively charged amino acid at the N-terminal. These sequences have no activity in both ORAC and HORAC.
TABLE IV | |||
Tradename | Sequence | ORAC | HORAC |
AC-SYN1 | Ac-EEVKRK-NH2 | No capacity | No capacity |
(SEQ ID: 7) | |||
AC-SYN2 | Ac-EELMSDIKK-NH2 | No capacity | No capacity |
(SEQ ID: 8) | |||
AC-SNP3 | Ac-EEMLERQRR-NH2 | No capacity | No capacity |
(SEQ ID: 9) | |||
AC-SNP4 | Ac-DESLESTRRM- | No capacity | No capacity |
NH2 | |||
(SEQ ID: 10) | |||
AC-SNP5 | Ac-EEMQRRKKK-NH2 | No capacity | No capacity |
(SEQ ID: 11) | |||
Table V shows the results obtained for short chain polypeptides having a positively charged amino acid at the N-terminal.
TABLE V | |||||
Tradename | Sequence | ORAC | HORAC | SORAC | |
CP2 | RRHM | 1204 | 321448 | 6(IC25) | |
(SEQ ID NO: 1) | |||||
AO2.1 | RYHM | 5390 | 131574 | — | |
(SEQ ID NO: 4) | |||||
AO2 | RYHW | 9328 | 41882 | 4(IC25) | |
(SEQ ID NO: 3) | |||||
CP2.6 | RRH | 0 | 41073 | — | |
AO1 | HYHY | 4748 | 33489 | 6(IC25) | |
(SEQ ID NO: 2) | |||||
CP2.5 | HRHM | 952 | 10192 | — | |
(SEQ ID NO: 12) | |||||
Table VI shows the results obtained for polypeptides having four or less amino acids.
TABLE VI | |||||
Charge | |||||
Tradename | Sequence | ORAC | HORAC | SORAC | (pH 7) |
CP2 | RRHM | 1204 | 321448 | 6(IC25) | 2.5+ |
(SEQ ID NO: 1) | |||||
AO2.1 | RYHM | 5390 | 131574 | 1.5+ | |
(SEQ ID NO: 4) | |||||
AO2 | RYHW | 9328 | 41882 | 4(IC25) | 1.5+ |
(SEQ ID NO: 3) | |||||
CP2.6 | RRH | 0 | 41073 | 2.5+ | |
AO1 | HYHY | 4748 | 33489 | 6(IC25) | 1+ |
(SEQ ID NO: 2) | |||||
CP2.5 | HRHM | 952 | 10192 | 2+ | |
(SEQ ID NO: 12) | |||||
IMM2 | YHFR | 3036 | 5(IC25) | 1+ | |
(SEQ ID NO: 13) | |||||
RED18 | WrYr-NH2 | 4758 | 2982 | No capacity | 2+ |
RED25 | WKYK-NH2 | 4168 | 2476 | No capacity | 2+ |
(SEQ ID NO: 5) | |||||
RED21 | WRyR-NH2 | 4816 | 2472 | 7(IC25) | 2+ |
RED24 | wRYR-NH2 | 4077 | 2225 | No capacity | 2+ |
RED23 | WRYR | 4091 | 2089 | No capacity | 2+ |
(SEQ ID NO: 6) | |||||
RED22 | wRyR-NH2 | 5383 | 1686 | No capacity | 2+ |
RED20 | WrYR-NH2 | 4448 | 1666 | No capacity | 2+ |
RED6 | WRYR-NH2 | 4488 | 1548 | No capacity | 2+ |
(SEQ ID NO: 6) | |||||
RED19 | WRYr-NH2 | 4350 | 1457 | No capacity | 2+ |
Table VII shows the results obtained for a short chain polypeptide having a positive charge (2.5+) is important to contributing to HORAC activity, the lack of a hydrophobic/neutrally charged amino acid has given this sequence no capacity in ORAC activity.
TABLE VII | ||||
Tradename | Sequence | ORAC | HORAC | SORAC |
CP2.6 | RRH | No capacity | 41073 | — |
Table VIII below indicates that the presence of at least one neutral and/or hydrophobic amino acid in the chain after the N-terminal amino acid contributes to the ORAC activity.
TABLE VIII | ||||
Tradename | Sequence | ORAC | HORAC | SORAC |
AO2 | RYHW | 9328 | 41882 | 4(IC25) |
(SEQ ID NO: 3) | ||||
S1 | HWPY | 5955 | — | 13(IC25) |
(SEQ ID NO: 14) | ||||
S2 | YWPW | 5917 | — | No capacity |
(SEQ ID NO: 15) | ||||
RED29 | wRyRw-NH2 | 5512 | — | No capacity |
AO2.1 | RYHM | 5390 | 131574 | |
(SEQ ID NO: 4) | ||||
RED22 | wRyR-NH2 | 5383 | 1686 | No capacity |
RED27 | Ac-wRyR-NH2 | 5342 | — | No capacity |
RED28 | wRyRy-NH2 | 5216 | — | 3(IC25) |
RED21 | WRyR-NH2 | 4816 | 2472 | 7(IC25) |
RED18 | WrYr-NH2 | 4758 | 2982 | No capacity |
AO1 | HYHY | 4748 | 33489 | 6(IC25) |
(SEQ ID NO: 2) | ||||
RED31 | wRwR-NH2 | 4652 | — | No capacity |
RED6 | WRYR-NH2 | 4488 | 1548 | No capacity |
(SEQ ID NO: 6) | ||||
RED26 | RwRyR-NH2 | 4461 | — | No capacity |
RED20 | WrYR-NH2 | 4448 | 1666 | No capacity |
RED19 | WRYr-NH2 | 4350 | 1457 | No capacity |
RED25 | WKYK-NH2 | 4168 | 2476 | No capacity |
(SEQ ID NO: 5) | ||||
RED23 | WRYR | 4091 | 2089 | No capacity |
(SEQ ID NO: 6) | ||||
RED24 | wRYR-NH2 | 4077 | 2225 | No capacity |
RED32 | RyR-NH2 | 3385 | — | No capacity |
IMM1 | HWRF | 2422 | — | 5(IC25) |
(SEQ ID NO: 16) | ||||
RED9 | fkwR-NH2 | 2202 | 752 | No capacity |
RED7 | kfRw-NH2 | 2120 | 1124 | No capacity |
RED11 | CWRYR-NH2 | 2007 | 625 | No capacity |
(SEQ ID NO: 17) | ||||
RED2 | KRKYWW-NH2 | 1837 | 1063 | No capacity |
(SEQ ID NO: 18) | ||||
Table IX shows results obtained for polypeptides containing a negatively charged amino acid. These sequences have no activity in both ORAC and HORAC. It shows that despite the presence of positively charge amino acids and neutral/hydrophobic amino acids, these peptide sequences have no antioxidant activity.
TABLE IX | |||
Tradename | Sequence | ORAC | HORAC |
AC-SYN1 | Ac-EEVKRK-NH2 | No capacity | No capacity |
(SEQ ID: 7) | |||
AC-SYN2 | Ac-EELMSDIKK-NH2 | No capacity | No capacity |
(SEQ ID: 8) | |||
AC-SNP1 | Ac-RRMLQLVEE-NH2 | No capacity | No capacity |
(SEQ ID: 19) | |||
AC-SNP3 | Ac-EEMLERQRR-NH2 | No capacity | No capacity |
(SEQ ID: 9) | |||
AC-SNP4 | Ac-DESLESTRRM-NH2 | No capacity | No capacity |
(SEQ ID: 10) | |||
AC-SNP5 | Ac-EEMQRRKKK-NH2 | No capacity | No capacity |
(SEQ ID: 11) | |||
AC-SNP6 | Ac-Valérate- | No capacity | No capacity |
EEMQRRKKK-NH2 | |||
(SEQ ID: 11) | |||
AC-SNP7 | Ac-KKKEEMQRR-NH2 | No capacity | No capacity |
(SEQ ID: 20) | |||
The above description is presented to enable a person skilled in the art to make and use the invention, and is provided in the context of a particular application and its requirements. Various modifications to the preferred embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments and applications without departing from the spirit and scope of the invention. Thus, this invention is not intended to be limited to the embodiments shown, but is to be accorded the widest scope consistent with the principles and features disclosed herein. In this regard, certain embodiments within the invention may not show every benefit of the invention, considered broadly.
Claims (7)
1. A short chain polypeptide, comprising:
4 amino acids bonded to form a polypeptide chain having an amine-terminal end and carboxyl terminal end;
wherein the carboxy-terminal end is amidated;
wherein the net charge of the polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, and the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group;
and wherein the polypeptide is selected from the group consisting of formula (I), formula (II) and formula (III):
2. A method to prepare a composition having antioxidant properties, comprising:
adding the short chain polypeptide of claim 1 to the composition.
3. A composition, comprising:
the short chain polypeptide of claim 1 in a physiologically or pharmaceutically acceptable medium.
4. The composition of claim 3 , further comprising an antioxidant that is not a short chain polypeptide.
5. The composition of claim 3 , further comprising a nutritional ingredient selected from the group consisting of a fat, an oil and a protein.
6. The composition of claim 3 , wherein a content of the short chain polypeptide is from 0.01 to 40 wt % based on a total weight of the composition.
7. A method for attenuating effects of free radicals on a keratinous material, comprising applying the composition of claim 3 , to the keratinous material of a subject in need thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/315,619 US9464111B2 (en) | 2014-06-26 | 2014-06-26 | Short peptides and a method of use as an antioxidant |
PCT/US2015/037727 WO2015200656A1 (en) | 2014-06-26 | 2015-06-25 | Short peptides and a method of use as an antioxidant |
US15/063,173 US9624265B2 (en) | 2014-06-26 | 2016-03-07 | Short peptides and a method of use as an antioxidant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/315,619 US9464111B2 (en) | 2014-06-26 | 2014-06-26 | Short peptides and a method of use as an antioxidant |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/063,173 Continuation US9624265B2 (en) | 2014-06-26 | 2016-03-07 | Short peptides and a method of use as an antioxidant |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150376234A1 US20150376234A1 (en) | 2015-12-31 |
US9464111B2 true US9464111B2 (en) | 2016-10-11 |
Family
ID=54929779
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/315,619 Active US9464111B2 (en) | 2014-06-26 | 2014-06-26 | Short peptides and a method of use as an antioxidant |
US15/063,173 Active US9624265B2 (en) | 2014-06-26 | 2016-03-07 | Short peptides and a method of use as an antioxidant |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/063,173 Active US9624265B2 (en) | 2014-06-26 | 2016-03-07 | Short peptides and a method of use as an antioxidant |
Country Status (2)
Country | Link |
---|---|
US (2) | US9464111B2 (en) |
WO (1) | WO2015200656A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114478698B (en) * | 2021-12-30 | 2023-07-25 | 宜肌坊(厦门)生物科技有限公司 | Antioxidant short peptide M5, preparation method and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091569A2 (en) | 2003-04-15 | 2004-10-28 | Citramed Ltd. | Activated citrus peel extract |
CN1593646A (en) | 2004-07-16 | 2005-03-16 | 吉林大学 | Soybean peptide, its preparation and application |
US20050255176A1 (en) * | 2004-05-17 | 2005-11-17 | Burgess W P | Method for attenuating free radical formation resulting from bodily insult |
JP2006342107A (en) | 2005-06-09 | 2006-12-21 | Nitta Gelatin Inc | Cosmetic composition containing collagen peptide and method for producing the same |
JP2009091305A (en) | 2007-10-10 | 2009-04-30 | Yaizu Suisankagaku Industry Co Ltd | Novel peptide and method of manufacturing the same, and antioxidant |
US20110319347A1 (en) | 2009-03-11 | 2011-12-29 | Kiyoshi Nokihara | Antioxidant agent |
WO2012119989A2 (en) * | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
WO2013086020A1 (en) | 2011-12-09 | 2013-06-13 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
US20130316942A1 (en) | 2011-01-20 | 2013-11-28 | Josef Mograbi | Antioxidant, Anti-Inflammatory, Anti-Radiation, Metal Chelating Compounds And Uses Thereof |
JP2014015481A (en) | 2004-10-08 | 2014-01-30 | Snow Brand Milk Products Co Ltd | Peptide |
-
2014
- 2014-06-26 US US14/315,619 patent/US9464111B2/en active Active
-
2015
- 2015-06-25 WO PCT/US2015/037727 patent/WO2015200656A1/en active Application Filing
-
2016
- 2016-03-07 US US15/063,173 patent/US9624265B2/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091569A2 (en) | 2003-04-15 | 2004-10-28 | Citramed Ltd. | Activated citrus peel extract |
US20050255176A1 (en) * | 2004-05-17 | 2005-11-17 | Burgess W P | Method for attenuating free radical formation resulting from bodily insult |
CN1593646A (en) | 2004-07-16 | 2005-03-16 | 吉林大学 | Soybean peptide, its preparation and application |
JP2014015481A (en) | 2004-10-08 | 2014-01-30 | Snow Brand Milk Products Co Ltd | Peptide |
JP2006342107A (en) | 2005-06-09 | 2006-12-21 | Nitta Gelatin Inc | Cosmetic composition containing collagen peptide and method for producing the same |
JP2009091305A (en) | 2007-10-10 | 2009-04-30 | Yaizu Suisankagaku Industry Co Ltd | Novel peptide and method of manufacturing the same, and antioxidant |
US20110319347A1 (en) | 2009-03-11 | 2011-12-29 | Kiyoshi Nokihara | Antioxidant agent |
US20130316942A1 (en) | 2011-01-20 | 2013-11-28 | Josef Mograbi | Antioxidant, Anti-Inflammatory, Anti-Radiation, Metal Chelating Compounds And Uses Thereof |
US8802635B2 (en) | 2011-01-20 | 2014-08-12 | Oneday—Biotech And Pharma Ltd. | Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof |
US20140315787A1 (en) | 2011-01-20 | 2014-10-23 | Josef Mograbi | Antioxidant, Anti-Inflammatory, Anti-Radiation, Metal Chelating Compounds And Uses Thereof |
WO2012119989A2 (en) * | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
WO2013086020A1 (en) | 2011-12-09 | 2013-06-13 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
US20140294796A1 (en) | 2011-12-09 | 2014-10-02 | D. Travis Wilson | Aromatic-cationic peptides and uses of same |
Non-Patent Citations (11)
Title |
---|
Alexander A. Boldyrev, et al., "Carnosine, the Protective, Anti-aging Peptide" Bioscience Reports, vol. 19, No. 6, 1999, (pp. 581-587). |
Barbara S. Berlett, et al., "Protein Oxidation in Aging, Disease, and Oxidative Strees" Minireview, Jbc, The Journal of Biological Chemistry, Affinity Sites, J. Biol. Chem. 1997, vol. 272, No. 33, (pp. 20313-20316). |
Gulizar Atmaca, "Antioxidant Effects of Sulfur-Containing Amino Acids" Yonsei Medical Journal, vol. 45, No. 5, (pp. 776-788), 2004. |
Hailong Yang, et al., "Antioxidant Peptidomics Reveals Novel Skin Antioxidant System" Research, Skin Antioxidant Peptidomics, Molecular & Cellular Proteomics 8.3, This pa;er is available on line at http://www.mcponline.org, 2009 by The American Society for Biochemistry and Molecular Biology, Inc. (pp. 571-583) 2009. |
Hang Guo, et al. "Food Chemistry", Structures and properties of antioxidative peptides derived from royal jelly protein, vol. 113, No. 1, 2009, pp. 238-245. |
Hau-Ming Chen, et al., "Antioxidative Properties of Histidine-Containing Peptides Designed from Peptide Fragments Found in the Digests of a Soybean Protein" Published on Web Jan. 19, 1998, American Chemical Society, J. Agric. Food Chem., vol. 46, No. 1, 1998 (pp. 49-53). |
International Search Report and Written Opinion issued on Aug. 11, 2015 in PCT/US2015/037727. |
Kesheng Zhao, et al., "Cell-Permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane Inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury" Jbc, The Journal of Biological Chemistry, Affinity Sites, J. Biol. Chem. 2004, vol. 279, No. 33, (pp. 34682-34690). |
Mingsheng Xu, et al., "Antioxidative Activity of Hen Egg Ovalbumin Hydrolysates" Original Article, Asia Pac J Clin Nutr 2007; 16 (suppl 1): (pp. 178-182). |
Shaheen B. Mowla, et al., "A novel Stress-inducible Antioxidant Enzyme Identified from the Resurrection Plant Xerophyta viscosa Baker" Original Article, Planta (2002) 215: (pp. 716-726). |
U.S. Appl. No. 14/315,585, filed Jun. 26, 2014, Sabatier, et al. |
Also Published As
Publication number | Publication date |
---|---|
US20160184208A1 (en) | 2016-06-30 |
US9624265B2 (en) | 2017-04-18 |
WO2015200656A1 (en) | 2015-12-30 |
US20150376234A1 (en) | 2015-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103254278B (en) | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same | |
JP5018171B2 (en) | Plant-derived activator and extracellular matrix production promoter | |
JPWO2007148739A1 (en) | Plant-derived cell activator, anti-aging agent, and extracellular matrix production promoter | |
EP3974441A1 (en) | Novel peptide compound or pharmaceutically acceptable salt thereof | |
KR20110012148A (en) | Hydroxycinnamoyl-peptide derivatives, process for producing the same and cosmetic composition comprising the same | |
KR101741002B1 (en) | Peptide having antioxidant activity and composition comprising thereof | |
US9624265B2 (en) | Short peptides and a method of use as an antioxidant | |
KR101948238B1 (en) | Conjugate of minoxidil and peptide | |
JP2009292756A (en) | Polyamine-containing stress-mitigating agent | |
US9795551B2 (en) | Tetrapeptides and a method of use as an antioxidant | |
JP2021176330A (en) | Conjugate of salicylic acid and peptide | |
JP5578160B2 (en) | Plant-derived activator and extracellular matrix production promoter | |
JP5714206B2 (en) | Antioxidant | |
KR101433419B1 (en) | Hydroxycinnamoyl-amino acidyl-hydroxamic acid derivatives | |
JP2021075495A (en) | Anti-inflammatory agent | |
Amar-Yuli et al. | Controlled release and delivery technology of biologically active proteins and peptides | |
EP4118978A1 (en) | Oral composition for inhibiting elastase and use thereof, elastase inhibitor, and method for inhibiting elastase activity by oral intake of elastase inhibitor | |
TWI821502B (en) | Peptide, composition and method for anti-hair graying | |
KR101945947B1 (en) | Protocatechuic acid derivative, method for production thereof and external skin composition containing the same | |
CN103443118A (en) | Novel peptide | |
KR101945946B1 (en) | Gentisic acid derivative, method for production thereof and external skin composition containing the same | |
US11351266B2 (en) | Conjugate of isotretinoin and peptide | |
KR101942844B1 (en) | Gallic acid derivative, method for production thereof and external skin composition containing the same | |
CN116693614A (en) | Sea cucumber antioxidant polypeptide and application thereof | |
KR101661349B1 (en) | Composition with Antioxidation Function Containing ACQ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: L'OREAL, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YOUNG, ANNE;REEL/FRAME:033211/0472 Effective date: 20140620 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |